Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Assessment of humoral immune function in chronic obstructive pulmonary disease (COPD) patients: an innovative strategy for COPD phenotyping (AiCOP)

FY 2022-23

Summary
Chronic obstructive pulmonary disease (COPD) is a global health concern that was identified as the 3rd leading cause of death. A majority of COPD patients experience disease flare-ups known as recurrent exacerbations, leading to accelerated decline in lung function and quality of life. Despite treatment with standard medications like corticosteroids, exacerbations tend to be frequent in these COPD patients. The cause of COPD exacerbations is unclear, but likely multifactorial. It has been recognized that 50% of exacerbations are triggered by recurrent infections. Thus, our study will answer the novel research question: whether people with recurrent COPD exacerbations may be rendered to an immunocompromised state that increases infection risk. Traditionally, immune status is tested by measuring the antibody levels one produces after administration of a pneumococcal vaccine, called a vaccine response. As most individuals with COPD have received a pneumococcal vaccine and previous vaccination interferes with accurate interpretation of test results and immune response. The approach to test our research question is innovative in that we plan to use a well-accepted, Typhoid vaccine response, with low vaccine coverage in Canada. Using this approach, we hypothesize that people with a history of recurrent exacerbations will have a lower degree of vaccine response, indicating a weaker immune system. This study will open up a new paradigm of diagnosis and treatment for people with COPD. Patients may be offered alternative, non-standard immunoglobulin-replacement therapies to prevent future exacerbations. Overall the study has the potential to improve health outcomes in patients and to enable clinicians and scientists to use immune function as a biomarker for COPD phenotyping.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486188
Name
Patel Zil
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessment of humoral immune function in chronic obstructive pulmonary disease (COPD) patients: an innovative strategy for COPD phenotyping (AiCOP)
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Exacerbation Risk Ratio; Acute Exacerbations Of Copd (Aecopd); Adaptive Immunity; Chronic Obstructive Pulmonary Disease (Copd); Humoral Immunodeficiency; Immunoglobulins; Inflammation; Polysaccharide Vaccine Response; Respiratory Infections; T-Cell-Independent Antibody Response
Abstract
Chronic obstructive pulmonary disease (COPD) is a global health concern that was identified as the 3rd leading cause of death. A majority of COPD patients experience disease flare-ups known as recurrent exacerbations, leading to accelerated decline in lung function and quality of life. Despite treatment with standard medications like corticosteroids, exacerbations tend to be frequent in these COPD patients. The cause of COPD exacerbations is unclear, but likely multifactorial. It has been recognized that 50% of exacerbations are triggered by recurrent infections. Thus, our study will answer the novel research question: whether people with recurrent COPD exacerbations may be rendered to an immunocompromised state that increases infection risk. Traditionally, immune status is tested by measuring the antibody levels one produces after administration of a pneumococcal vaccine, called a vaccine response. As most individuals with COPD have received a pneumococcal vaccine and previous vaccination interferes with accurate interpretation of test results and immune response. The approach to test our research question is innovative in that we plan to use a well-accepted, Typhoid vaccine response, with low vaccine coverage in Canada. Using this approach, we hypothesize that people with a history of recurrent exacerbations will have a lower degree of vaccine response, indicating a weaker immune system. This study will open up a new paradigm of diagnosis and treatment for people with COPD. Patients may be offered alternative, non-standard immunoglobulin-replacement therapies to prevent future exacerbations. Overall the study has the potential to improve health outcomes in patients and to enable clinicians and scientists to use immune function as a biomarker for COPD phenotyping.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Patel, Zil
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~